Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Related REGN
Sanofi And Regeneron Report Positive Top-Line Results From Nine Phase 3 Trials Of Alirocumab In People With Hypercholesterolemia
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study
Related AGN
Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest EPS
Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures
Allergan to Slash 13% of its Global Workforce (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Posted-In: Analyst Color Analyst Ratings


Most Popular

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters